This month the National Cancer Institute began gathering patients for the Molecular Profiling-based Assignment of Cancer Therapeutics (M-PACT) trial among patients with metastatic solid tumors not responding to standard treatments. The study will begin by screening hundred of patients for 391 mutations in 20 genes that may respond to specific targeted therapies. Next, 180 patients will be randomly split into arms that either receive or don’t receive drugs that thought to target a specific mutation or pathway in their tumor. The primary outcomes will be response rates and/or 4-month progression-free survival, with that data collected by March 2017. Among its results, NCI says, M-PACT should give a good snapshot of the state of the art in improving outcomes via targeted therapies.